<- Go Home
Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.
Market Cap
$108.3M
Volume
132.7K
Cash and Equivalents
$129.2M
EBITDA
-$33.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$3.19
52 Week Low
$1.65
Dividend
N/A
Price / Book Value
0.87
Price / Earnings
-3.22
Price / Tangible Book Value
0.87
Enterprise Value
-$20.9M
Enterprise Value / EBITDA
0.64
Operating Income
-$34.0M
Return on Equity
23.80%
Return on Assets
-14.50
Cash and Short Term Investments
$129.2M
Debt
$16.0K
Equity
$125.0M
Revenue
N/A
Unlevered FCF
-$14.3M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium